| HOME >> BIOLOGY >> TECHNOLOGY |
"I'd like to recognise Kevin Rakin as a leader of this business during its integration into Shire; and we wish him well in his new endeavours. "
Says Jeff Jonas:
"Shire's Regenerative Medicine business has so much potential; it serves a growing patient population with unmet needs and we have an excellent, differentiated product in DERMAGRAFT, already commercialised for diabetic foot ulcers. We're exploring other possible indications for DERMAGRAFT and we believe we can expand its use into new geographies. The science and technology in regenerative medicine is developing well and we see many opportunities to acquire other exciting assets to build a robust and attractive pipeline. Leading this business to greater heights is a very exciting opportunity for me."
Further background on Jeff Jonas
Before joining Shire in 2008, he served as Executive Vice President at Isis Pharmaceuticals in charge of clinical and pre-clinical development, regulatory affairs, quality assurance and compliance, and had broad responsibility for the product pipeline.
Prior to this, Jeff was Chief Medical Officer and Executive Vice President at Forest Laboratories, Inc.
He began his career at Upjohn Laboratories where he advanced to the position of Chief Medical Officer.
Jeff has also been a successful entrepreneur. He founded and led AVAX Technologies, a leader in autologous cell therapy and individualized therapy. Dr. Jonas led AVAX through several successful financings, including an initial public offering in 1997.
In 2001, he co-founded SCEPTOR Industries, a biotechnology company involved in biodefense surveillance.
Jeff has published more than 70 scientific papers and chapters and has received a number of awards.
Jeff received his M.D. from Harvard Medical School and completed a residency in psychiatry at Harvard. Shortly thereafter, he was appoi
'/>"/>
| SOURCE Shire plc Copyright©2012 PR Newswire. All rights reserved |